Amicus Therapeutics' GAAP loss for 2021 was $250.46 million, down 9.5% from $276.852 million in the previous year. Revenue increased 17.1% to $305.514 million from $260.886 million a year earlier.
Amicus Therapeutics' GAAP loss for 2021 was $250.46 million, down 9.5% from $276.852 million in the previous year. Revenue increased 17.1% to $305.514 million from $260.886 million a year earlier. 
ir.amicusrx.com
English (US) 